AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00554177
Drug: Medicane (mifepristone)
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 1200mg, Administered 2-3 days apart
Trial: NCT00554177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 1200mg, administered 2-3 days apart
Trial: NCT03535272
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo manufactured to mimic pepto bismol
Trial: NCT03737851
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for infusion
Trial: NCT01077154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously for up to 5 years
Trial: NCT04566445
Drug: GT005: Medium Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will test two doses of GT005: Medium Dose and High Dose.
Trial: NCT04566445
Drug: GT005: High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will test two doses of GT005: Medium Dose and High Dose.
Trial: NCT03787043
Drug: FDC(MP-513 10mg/Metformin XR 750mg)
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01067547
Drug: Iron Sucrose.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total dose of iron sucrose given will be individualised by calculating their iron deficit.
Trial: NCT01432782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 4 ml
Trial: NCT02653261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of saline
Trial: NCT04215809
Drug: APG2575
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG2575 investigation drug in ramp up dosing
Trial: NCT00859027
Drug: Placebo risedronate oral tablet
RxNorm normalized name: risedronate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet by mouth every week as directed
Trial: NCT00388674
Drug: Other anti-HBV medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
Trial: NCT01635686
Drug: DWP422 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01635686
Drug: ENBREL 25MG PFS INJ.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01327183
Drug: RO4905417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
Trial: NCT01327183
Drug: RO4905417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
Trial: NCT01327183
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv infusion, completed at least 1 hour and up to 24 hours before PCI
Trial: NCT04945629
Drug: Blood clot and simple suture
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filling the alveolus with blood clot
Trial: NCT01866995
Drug: Raylis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
Trial: NCT01744782
Drug: RP103
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
Trial: NCT04531059
Drug: Tetracycline,Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT04531059
Drug: Minocycline,Metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT03401398
Drug: Hydrocortisone, sodium succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
Trial: NCT03401398
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
Trial: NCT03785106
Drug: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Trial: NCT01047969
Drug: Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
Trial: NCT01284049
Drug: Intralipid 20%®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
Trial: NCT01284049
Drug: OMEGAVEN 10%®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
Trial: NCT02403687
Drug: Diclofenac Sodium 3%
RxNorm normalized name: Diclofenac Sodium 3% Topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compound topical cream
Trial: NCT02403687
Drug: Flurbiprofen 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compound topical cream
Trial: NCT00504842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00438932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanthanum Carbonate placebo given three times a day with meals.
Trial: NCT02403687
Drug: Meloxicam 0.09%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compound topical cream
Trial: NCT00008255
Drug: INS316
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00354731
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
Trial: NCT01416831
Drug: High-dose IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
Trial: NCT01743768
Drug: SB010
RxNorm normalized name: CATH,EXTERN SURESTEP START KIT #MECSB010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n=19), receiving the active drug substance.
Trial: NCT01743768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n=19), receiving placebo.
Trial: NCT04682639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
Trial: NCT02128451
Drug: Meperdine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
Trial: NCT02128451
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
Trial: NCT00883740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
Trial: NCT04360135
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive acetaminophen the day before surgery
Trial: NCT04360135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive placebo the day before surgery
Trial: NCT01094912
Drug: opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01818414
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg of buccal folic acid, 3 hours prior to planned D\&E
Trial: NCT00295308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules daily
Trial: NCT01890109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection
Trial: NCT01286207
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active standard care
Trial: NCT02205047
Drug: 5-fluorouracil or Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01293383
Drug: LEO 90105
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment
Trial: NCT01383954
Drug: Diclofenac Gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
Trial: NCT00450177
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group
Trial: NCT00566618
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I.
Trial: NCT02535247
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00133094
Drug: Simvastin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04006691
Drug: UGN-101 instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
Trial: NCT02453867
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
Trial: NCT02331069
Drug: Dextrose 5% (D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
Trial: NCT03999229
Drug: SNO
RxNorm normalized name: Sno Pilo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-nitrosylating agent (SNO) Inhalation
Trial: NCT03999229
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline transfusion
Trial: NCT01653223
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months.
Trial: NCT03406780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00238940
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03869736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
Trial: NCT00361491
Drug: SSR149415
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01791647
Drug: myoinositol 1500 mg
RxNorm normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04491955
Drug: MSB0011359C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
Trial: NCT01580488
Drug: B LEO 35299 20 mg/g cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 3 weeks
Trial: NCT01580488
Drug: F LEO 35299 10 mg/g solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 3 weeks
Trial: NCT01079078
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04160676
Drug: Hydrocortisone, Ascorbic acid, Thiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrocortisone, ascorbic acid, and thiamine
Trial: NCT04160676
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT03964220
Drug: Inhaled Corticosteroid/Long-acting beta-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
Trial: NCT01177319
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00814619
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00145652
Drug: Neo-Recormon and Venofer
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01330615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
Trial: NCT02478398
Drug: Self-injectable epinephrine
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
Trial: NCT03949283
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.
Trial: NCT06520267
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
Trial: NCT03620825
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
Trial: NCT02007187
Drug: Danhong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
Trial: NCT02007187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Trial: NCT00718081
Drug: Oral sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosage of sufentanil
Trial: NCT00718081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosage of placebo
Trial: NCT00014755
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04049669
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
Trial: NCT01959230
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution to be applied as directed.
Trial: NCT00679094
Drug: Bowman-Birk inhibitor concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02710734
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Trial: NCT02710734
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Trial: NCT04221217
Drug: Icosapent
RxNorm normalized name: Icosapent
DrugBank: Icosapent (DB00159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icosapent (MND-2119) capsules.
Trial: NCT05498896
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05498896
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT02797275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: respiratory inhaler with no medication
Trial: NCT04271202
Drug: Emgality 120 MG in 1 ML Prefilled Syringe
RxNorm normalized name: Emgality 120 MG in 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
Trial: NCT04094688
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04094688
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02651428
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
Trial: NCT04588298
Drug: AZD9833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9833 tablets will be administered orally.
Trial: NCT00639158
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg capsule, daily, 12 weeks
Trial: NCT00639158
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule, daily, 12 weeks